Barnes To Moderate at 2021 Rx Summit

Michael C. Barnes, JD, Principal Attorney at Sequel Legal and Chairman of the Center for U.S. Policy, will moderate three separate sessions at the 2021 Rx Drug Abuse & Heroin Summit. Topics will include informed addiction policy, post-overdose interventions, and addressing social determinants of health in addiction treatment. The annual conference will take place online April 5-8.  Registration for 2021 Rx Summit is still open, and the full agenda is […]

Barnes To Speak at 2021 Pharmacist Conference

Michael C. Barnes, JD, Principal Attorney at Sequel Legal and Chairman of the Center for U.S. Policy, will speak at the American Pharmacists Association (APhA) 2021 Annual Meeting on Monday, March 15. Mr. Barnes will co-present the session, entitled “Don’t ‘Just Say No’: Preventing Diversion and Addressing Medical Needs,” with Jake Nichols, PharmD, CEO of Professional Recovery Resources. Mr. Barnes will provide an overview of federal and state […]

Pain Care Legislation & Policy Update

On June 17, 2020, Michael Barnes, JD presented alongside Wade Delk, Government Affairs Director of the American Society for Pain Management Nursing (ASPMN), for the Providers Clinical Support System (PCSS) 2020 Pain Care Legislation and Public Policy Webinar. Mr. Barnes and Mr. Delk provided an update on state and federal legislative and regulatory actions and […]

DEA Temporarily Relaxes Telemedicine Standards for Prescribing Buprenorphine During COVID-19 Outbreak

The Drug Enforcement Administration (DEA) has temporarily relaxed the federal requirements for prescribing buprenorphine for opioid use disorder (OUD) via telemedicine during the COVID-19 public health emergency. As a general rule, the federal Controlled Substances Act (CSA) requires a valid prescription before a controlled prescription medication may be delivered, distributed, or dispensed by means of […]

FORE Issues Opinion Letter on Prescribing Buprenorphine with Telemedicine During COVID-19 Outbreak

The COVID-19 outbreak has presented extraordinary challenges in prescribing buprenorphine to new and existing patients with opioid use disorder (OUD). Telemedicine presents an opportunity to reach these patients and promote continuity of care; however, rapidly evolving circumstances have caused confusion among many practitioners as to their rights and obligations under federal law when prescribing controlled […]